Montelukast

Asthma

Kafrelsheikh UniversitySmall moleculePhase 4 / ApprovedActive

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

11 Active assets in the Asthma cohort.

Asset / Sponsor	Phase	Rating
Budesonide New York City Health and Hospitals Corporation	Phase 4	BBB
SALMETEROL Mundipharma (China) Pharmaceutical Co. Ltd	Phase 4	BBB
Flixotide GlaxoSmithKline	Phase 4	BBB
Mirabegron Kafrelsheikh University	Phase 4	BB
MK-0476 Organon and Co	Phase 4	BB

View all 48 →

Same molecule, other indications

Montelukast is also rated in:

metabolic dysfunction-associated steatohepatitisDormant

BBB

Indicative ·

73 / 100

Fabry diseaseDormant

BB

Indicative ·

69 / 100

sickle cell diseaseDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.